Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist.

× No keyword cloud information.

11 in total

1. Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.

Authors: G A Kennett; F Bailey; D C Piper; T P Blackburn
Journal: Psychopharmacology (Berl) Date: 1995-03 Impact factor: 4.530

2. Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors.

Authors: G Maura; M Marcoli; O Pepicelli; C Rosu; C Viola; M Raiteri
Journal: Br J Pharmacol Date: 2000-08 Impact factor: 8.739

3. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.

Authors: Soo-Kyung Kim; Youyong Li; Ravinder Abrol; Jiyoung Heo; William A Goddard
Journal: J Chem Inf Model Date: 2011-02-07 Impact factor: 4.956

4. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

Authors: G S Baxter; O E Murphy; T P Blackburn
Journal: Br J Pharmacol Date: 1994-05 Impact factor: 8.739

5. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Authors: G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn
Journal: Br J Pharmacol Date: 1996-02 Impact factor: 8.739

6. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

Authors: D W Bonhaus; C Bach; A DeSouza; F H Salazar; B D Matsuoka; P Zuppan; H W Chan; R M Eglen
Journal: Br J Pharmacol Date: 1995-06 Impact factor: 8.739

N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist.

1. Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.

2. Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors.

3. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.

4. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

5. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

6. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

7. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.

8. Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein.

9. Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.

10. In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay.